Who is sponsoring NCT00926614?

NCT00926614 is sponsored by Brooke Army Medical Center.

What condition does NCT00926614 study?

NCT00926614 studies Hepatitis c.

What drugs are being tested in NCT00926614?

Interventions: pioglitazone (Actos), atorvastatin (Lipitor).

What is the status of NCT00926614?

NCT00926614 is currently COMPLETED.

Last reviewed 2012-02-13 · How we verify

48 Week Pilot Trial Assessing the Efficacy of Pioglitazone, Atorvastatin, Pegasys and Weight Based Ribavirin in Chronic Hepatitis C, Genotype 1 Patients Who Have Previously Relapsed or Did Not Respond to PegInterferon /Ribavirin Therapy

NCT00926614 Phase 4 COMPLETED

The aim of the study will be to determine if an insulin sensitizing thiazolidinedione plus a lipid lowering agent (statin) improves sustained virologic response rates in patients who have previously not responded or relapsed on standard pegylated interferon and ribavirin therapy.

Details

Lead sponsor	Brooke Army Medical Center
Phase	Phase 4
Status	COMPLETED
Enrolment	20
Start date	2008-09
Completion	2011-12

Conditions

Hepatitis c

Interventions

pioglitazone (Actos)
atorvastatin (Lipitor)

Primary outcomes

Improvement is seen in insulin resistance patients to be in a position to respond more favorably to current antiviral therapy consisting of pegylated interferon and ribavirin. — 36 weeks

Countries

United States